B.Riley analyst Kalpit Patel reiterated a Buy rating and $40.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst comments "Takeover ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE